GlobalData on MSN12h
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
The Global Legal Post1d
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...
FiercePharma1d
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
Pfizer wins bid to invalidate GSK’s patents over RSV vaccine
Pfizer’s victory in London court invalidates two GSK patents for respiratory syncytial virus (RSV) vaccine. GSK plans to ...
MM&M2d
Skyrizi notches top pharma, Rx brand spot for Q3 2024
Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...
Top Companies, Marketers, CEOs, Products, and Initiatives Were Celebrated During Trailblazer Gala on October 1st
On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...